RxDoctor Payments Data

Edris Aman, MD

Cardiovascular Disease · Sacramento, CANPI 1437448511

Payments from drug & device makers

$515,555in general payments, 2019–2025

Across 392 payments — averaging $1315.19 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Abbott$264K
  • Philips North America LLC$192K
  • W. L. Gore & Associates, Inc.$43K
  • Siemens Medical Solutions USA, Inc.$14K
  • Boston Scientific$1K
  • Edwards Lifesciences$725
  • plus $782 from 10 others

What the payments were for

  • Consulting fees$385,47575%
  • Speaking & faculty fees$27,7905%
  • Grants$950%
  • Travel & lodging$91,58618%
  • Food & beverage$10,4782%
  • Education$1310%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$515,555 in reported general payments places this provider in the 95th percentile of 2,184 cardiovascular disease providers in California.

See all cardiovascular disease providers in California

Medicare billing

Part B allowed, 2024
$91,686
Medicare patients
1,007
Services billed
1,809

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban35$56,107
XareltoRivaroxaban16$27,946
EntrestoSacubitril/Valsartan17$27,023
JardianceEmpagliflozin12$17,828
Rosuvastatin Calcium51$1,670
Atorvastatin Calcium84$1,055
Metoprolol Succinate52$954
Flecainide Acetate15$794
Bisoprolol Fumarate23$732
Losartan Potassium29$598
Bumetanide18$514
Lisinopril26$467
Spironolactone35$446
Nitroglycerin22$355
Metoprolol Tartrate23$316

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$173$56,10735 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 2,184 cardiovascular disease providers in California.

Other cardiovascular disease in Sacramento

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →